News of the complete response letter (CRL) for bulevirtide, which is already on sale in other markets around the world, including Europe, as Hepcludex, came in remarks by Gilead's chief medical ...

Gilead Sciences is planning to file for approval of Hepcludex, its antiviral therapy for rare hepatitis D virus (HDV) in the US later this year, after the drug's safety and efficacy was shown in ...

Gilead is also strengthening its liver disease franchise with new treatments like Hepcludex. However, pipeline setbacks have been a concern for Gilead in 2024, a factor to watch out for in 2025.